QIAGEN N.V. (
Q4 2011 Earnings Conference Call
February 1, 2012 09:30 ET
Albert Fleury – Director IR North America
Peer Schatz – Chief Executive Officer
Roland Sackers – Chief Financial Officer
John Gilardi – Vice President and Corporate Communications and Investor Relations
Quintin Lai – Robert W. Baird
Doug Schenkel – Cowen and Company
Nandita Koshal – Barclays Capital
Tycho Peterson – JPMorgan
Jon Groberg – Macquarie
Martin Wales – UBS
Bill Quirk – Piper Jaffray
Romain Zana – Exane BNP Paribas
Peter Lawson – Mizuho Securities
Ladies and gentlemen, thank you for standing by. Welcome to the QIAGEN NV Investor and Analyst Conference Call on the Q4 Results 2011. Throughout today's recorded presentation, all participants will be in a listen-only mode. The presentation will be followed by a question-and-answer session. (Operator Instruction)
I would now like to turn the conference over to Albert Fleury, Director IR North America.
Albert Fleury – Director IR
Thank you. Good afternoon and welcome to the QIAGEN conference call to discuss our results for the fourth quarter and full year 2011. Joining me on the call are Peer Schatz, Chief Executive Officer, Roland Sackers, Chief Financial Officer and John Gilardi, Vice President and Corporate Communications and Investor Relations. A copy of this announcement and the presentation for this conference call can be downloaded from the Investor Relations section of our homepage at www.qiagen.com.
Moving onto Slide 2, before I turn the call over to Peer, please keep in mind that the following discussion and the responses to our questions reflect management’s view as of today, February 1, 2011. As we share information to help you better understand our business, we will make statements and provide responses that state our intentions, beliefs, expectations, or predictions of the future. These constitute forward-looking statements for the purpose of the Safe Harbor provision. These involve certain risks and uncertainties that could cause QIAGEN’s actual results to differ materially from those projected. QIAGEN disclaims any intention or obligation to revise any forward-looking statements. For a compete description of the risks and uncertainties, please refer to our Form 20-F filed with the U.S. Securities and Exchange Commission.